Scotland · NHS Scotland MSAN
Mesalazine (Asacol®) 400mg MR gastro-resistant tablets
MSAN(2024)18 · Level 2 · issued 27 Apr 2024
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| Valid until: discontinued - stock to be exhausted by late April 2024 | Discontinued | — |
| 1. Asacol® 400mg MR gastro-resistant tablets (pack size 168) was discontinued in March 2024; all | Discontinued | — |
| 2. Asacol® 400mg MR gastro-resistant tablets (pack size 84) was discontinued from 1st April 2024; | Discontinued | — |
| 3. Mesalazine (Octasa® MR) 400mg tablets remain available and can support a full uplift in | Available | — |
| 4. Mesalazine (Asacol®) 800mg MR gastro-resistant tablets remain available and able to support a | Available | — |
| 5. Other mesalazine tablet preparations, with different release characteristics, remain available | Available | — |
| Registration for access to the website is available to UK healthcare professionals and | Available | — |
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.